Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_EE057E94F72E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy.
Périodique
Critical reviews in oncology/hematology
Auteur⸱e⸱s
De Bari B., Porta L., Mazzola R., Alongi F., Wagner A.D., Schäfer M., Bourhis J., Ozsahin M.
ISSN
1879-0461 (Electronic)
ISSN-L
1040-8428
Statut éditorial
Publié
Date de publication
07/2016
Peer-reviewed
Oui
Volume
103
Pages
49-61
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The role of neoadjuvant and definitive radiotherapy combined or not to chemotherapy in the therapeutic approach to pancreatic cancer has not been yet elucidated. There is some evidence in favour of neoadjuvant local and/or systemic approaches that enable surgical resection in patients initially considered to be "borderline resectable". Nevertheless, most of these studies have been conducted using schedules of radiotherapy (treatment volumes, total doses, dose/fraction) that are nowadays considered not efficient enough and/or too toxic. Recently, stereotactic body radiation therapy (SBRT) has been proposed as a new therapeutic option for pancreatic cancer, both in the neoadjuvant and in the definitive setting. The aim of this study is to review the radiobiological and clinical evidences supporting hypofractionation in pancreatic cancer. Moreover, we performed an extensive review of available clinical and dosimetric data on SBRT in pancreatic cancer.
Mots-clé
Humans, Neoadjuvant Therapy, Pancreatic Neoplasms/radiotherapy, Radiosurgery/adverse effects, Treatment Outcome
Pubmed
Open Access
Oui
Création de la notice
14/06/2016 16:17
Dernière modification de la notice
08/06/2023 5:55
Données d'usage